DSpace Repository

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner

Show simple item record

dc.contributor Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Guardiola, M.
dc.contributor.author Echeverria, Patricia
dc.contributor.author González, Marta
dc.contributor.author Vallvé, Joan Carles
dc.contributor.author Puig, Jordi
dc.contributor.author Clotet, Bonaventura
dc.contributor.author Ribalta, J.
dc.contributor.author Negredo, Eugenia
dc.date.accessioned 2015-11-04T12:00:23Z
dc.date.available 2015-11-04T12:00:23Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Guardiola, M., Echeverria, P., González, M., Vallvé, J. C., Puig, J., Clotet, B., et al. (2015). Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. AIDS Research and Human Retroviruses, 31(9), 882-888. ca_ES
dc.identifier.issn 1931-8405
dc.identifier.uri http://hdl.handle.net/10854/4336
dc.description.abstract Introduction: HIV-infected patients treated with Highly Active Antiretroviral Therapy (HAART) may be predisposed to hypertriglyceridemia, which gives rise to a highly atherogenic lipid profile known as atherogenic dyslipidemia (AD). We propose that genetic variability leaves some HIV-infected patients more predisposed to AD than others [1,2]. Methods: This was a cross-sectional, observational study conducted in 468 antiretroviral-treated HIV-infected patients attending at the outpatient clinic of a tertiary hospital over a 6-month period, who were classified as normolipidemic (n 173) or presenting with AD (triglycerides: 1.7 mmol/L and HDLc B1.02 [men] or 1.28 mmol/L [women]) (n 148). Polymorphisms were identified in the APOA5, APOC3, LPL, CETP, HL, MTP, APOE, LRP5 and VLDLR genes. Results: Atherogenic dyslipidemia was detected in 31% of patients, most of whom were men (77%). This group was also older and had higher levels of remnant lipoprotein cholesterol (RLPc) than normolipidemic patients. The polymorphisms rs328 in LPL, rs708272 in CETP and rs1800588 in HL were 10 40% significantly more frequent in normolipidemic patients. At least 1 of these polymorphisms was detected in 90% of normolipidemic patients; in AD patients, the percentage decreased to 75% (p 0.003). This effect was dependent on both the allele and the dose of HAART and independent of the regimen administered. The protective combination showed a trend towards higher HDLc (1.13 [0.40] vs 1.24 [0.23] mmol/L), lower triglycerides (2.23 [2.34] vs 1.89 [1.24] mmol/L) and lower RLPc (16.41 [11.42] vs 12.99 [11.69] mmol/L). Conclusion: Polymorphisms in LPL, CETP and HL protect HIV-infected patients from developing AD in a dose-dependent manner. ca_ES
dc.format application/pdf
dc.format.extent 7 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Mary Ann Liebert ca_ES
dc.rights Tots els drets reservats ca_ES
dc.rights (c) Mary Ann Liebert
dc.subject.other Sida -- Tractament ca_ES
dc.title Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1089/aid.2015.0061
dc.rights.accesRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a SCOPUS ca_ES
dc.indexacio Indexat a WOS/JCR

Files in this item

Show simple item record

Search RIUVic


Browse

Statistics